Corporate Travel Management Limited (ASX:CTD) Updates FY25 Outlook
Corporate Travel Management Limited (ASX:CTD) updates FY25 outlook, adjusting revenue forecasts and highlighting strong client retention amid economic uncertainties.
Tag: Corporate Strategy & Guidance
Ark Mines Ltd (ASX:AHK) Secures $1.5M Through Share Placement
Ark Mines Ltd (ASX:AHK) raises $1.5 million through a share placement to advance its Sandy Mitchell rare earth project.
Pantoro Gold Limited (ASX:PNR) to Clear Debt After Repayment of Convertible Loan
Pantoro Gold Limited (ASX:PNR) repays its Convertible Loan Facility, becoming debt free ahead of schedule and reducing shareholder dilution.
BluGlass (ASX:BLG) Completes $2.3M Placement and Launches $6M SPP Offer
BluGlass (ASX:BLG) secures $2.3M through placement and launches a $6M SPP Offer to support growth in GaN laser technologies.
Perpetual Resources Limited (ASX:PEC) Announces Maiden Lithium Drilling Campaign
Perpetual Resources Limited (ASX:PEC) appoints ServDrill Brazil for its first lithium drilling campaign at the Igrejinha Project in Brazil’s Lithium Valley.
Wide Open Agriculture Limited (ASX:WOA) Clarifies Offtake and Distribution Agreement
Wide Open Agriculture (ASX:WOA) clarifies its offtake and distribution agreement with Univar, outlining market strategy and financial impact.
Imricor Medical Systems (ASX:IMR) Announces First Real-time MRI-guided Ablations at Semmelweis University
Imricor Medical Systems (ASX:IMR) initiates real-time MRI-guided ablation procedures at Hungary’s Semmelweis University, marking key European expansion.
Blackstone Minerals (ASX:BSX) Confirms High-Grade Copper-Gold Core at Mankayan
Blackstone Minerals (ASX:BSX) confirms a high-grade copper-gold core at Mankayan, reinforcing its position as a top undeveloped project globally.
Everest Metals Corporation Ltd (ASX:EMC) Secures CSIRO Support for Mt Edon Project
Everest Metals Corporation Ltd (ASX:EMC) secures CSIRO support with a $50,000 grant to advance mineral studies at the Mt Edon Project.
AdAlta Limited (ASX:1AD) Reports Q3 FY25 Progress on Immunotherapy Strategy
AdAlta Limited (ASX:1AD) reports significant advancements in its cellular immunotherapy strategy and outlines financial updates for Q3 FY25.